AI Article Synopsis
- Metformin shows potential as an adjunctive treatment for Acute Lymphoblastic Leukemia (ALL), enhancing the cancer-fighting effects of chemotherapy.
- A study involving 123 patients revealed that those treated with metformin experienced a lower relapse rate (6.5%) compared to those receiving standard chemotherapy alone (17.1%).
- Overall survival and disease-free survival rates were 43% and 47%, respectively, indicating that metformin might improve outcomes for ALL patients regardless of their initial biological risk.
Article Abstract
Background: Metformin has antineoplastic and cancer protective effects in vitro, sensitizing leukemia cells to chemotherapeutic agents, inducing apoptosis and cell cycle arrest.
Aim: To assess the effect of metformin on the induction stage in patients with ALL and its impact on overall survival and relapse.
Material And Methods: We included 123 patients treated with metformin and without metformin. The dose used was 850 mg PO at 8 h intervals. The survival analysis was used by Kaplan-Meier method, the difference between the distinct groups was performed using the log Rank test.
Results: The overall survival at a median follow up of 700 days of follow-up was 43%, with a disease-free survival of 47%. Regarding the treatment groups, patients with metformin had a lower rate of relapse compared to the group receiving only chemotherapy (6.5% vs 17.1%, p = 0.006).
Conclusions: The addition of metformin to the conventional treatment of ALL was associated with an improvement in survival, this association being independent of the type of biological risk at diagnosis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4067/s0034-98872018000700846 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!